Trial Profile

Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women With HER2-positive Breast Cancer (ARETTA)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Gonadotropin releasing hormone; Letrozole; Tamoxifen
Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms ARETTA

24 Oct 2023 Results of first report assessing feasibility of establishing a robust platform for multi-institutional biomarker driven oncology presented at the 48th European Society for Medical Oncology Congress
24 Oct 2023 Status changed to active, no longer recruiting, according to Results presented at the 48th European Society for Medical Oncology Congress
03 Mar 2023 Planned primary completion date changed from 10 Sep 2022 to 10 Sep 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com